DXC006 with immunotherapy or chemotherapy for small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug called DXC006, combined with either immunotherapy (checkpoint inhibitors) or platinum-based chemotherapy, for patients with small cell lung cancer. The goal is to see if this combination works better than standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Confirmed diagnosis of small cell lung cancer (SCLC) only—no mixed types with other cancers
- Age 18–75 years with good enough health to tolerate treatment (ECOG score 0–2)
- Life expectancy of at least 3 months
- Any previous cancer treatment side effects must be resolved to mild levels or gone completely
- Adequate organ function (liver, kidneys, heart, blood clotting)
- No brain tumors with symptoms, active infections requiring antibiotics, or severe bleeding problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests DXC014, a new drug, in people with advanced solid tumors, including prostate cancer. It aims to see if the drug is safe and effective.
This trial tests a combination of two experimental immunotherapy drugs (ivonescimab and cadonilimab) with standard chemotherapy for people with extensive-stage small cell lung cancer who have not had prior treatment. The goal is to see if this combination works better than chemo alone.
This trial tests a new drug, ZG006, combined with standard immunotherapy (PD-1/PD-L1 inhibitors) for people with advanced small cell lung cancer that hasn't been treated before. The goal is to find out if this combination works better than the current standard care.
This study tests three experimental drugs (tarlatamab, ZL-1310, and sometimes an immune-boosting drug) together to treat small cell lung cancer. The goal is to see if this combination can slow or shrink the cancer and help you live longer.
This trial tests a new drug, SYS6090, combined with other treatments for advanced non-small cell or small cell lung cancer that has spread and can't be removed by surgery. It aims to see if this combination can help shrink or control the cancer, and how safe it is for patients.
This trial tests a combination of low-dose radiation to the chest, immunotherapy (adebrelimab), and chemotherapy for extensive-stage small cell lung cancer. The goal is to see if this approach can help control the cancer better than standard treatments and potentially improve outcomes.
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.